Month: March 2021

Kidney Care Choices (KCC) Model

Update: The Kidney Care Choices (KCC) Model’s first Performance Year start date will now be January 1, 2022. CMS looks forward to sharing additional information when available.

Today, the Centers for Medicare & Medicaid Services (CMS) is announcing the Kidney Care Choices (KCC) Model start date for the first Performance Year will be delayed from April 1, 2021 to January 1, 2022. This change applies to all four options within the KCC Model: the CMS Kidney Care First (KCF) Option, and the three Comprehensive Kidney Care Contracting (CKCC) Options. Participants and stakeholders will be notified of any updates via listserv, as information becomes available. Updates for the KCC Model will also be posted to the KCC webpage.

Outreach and Education Resources for Partners During the Pandemic

As COVID-19 vaccines begin rolling out across the country, CMS is taking action to protect the health and safety of our nation’s patients and providers and keeping you updated on the latest COVID-19 resources from HHS, CDC and CMS.

With information coming from many different sources, CMS has compiled resources and materials to help you share important and relevant information on the COVID-19 vaccine with the people that you serve. You can find these and more resources on the COVID-19 Partner Resources Page and the HHS COVID Education Campaign page. We look forward to partnering with you to promote vaccine safety and encourage our beneficiaries to get vaccinated when they have the opportunity.

Promoting COVID-19 Vaccines in Your Community

CDC has designed a COVID-19 vaccine toolkit to help your organization educate community members about COVID-19 vaccines, raise awareness about the benefits of vaccination, and address common questions and concerns. It is full of free digital resources, templates, posters and ideas for how to work within your community to help promote the COVID vaccine.

HOW CAN YOU GET STARTED?

Know the COVID-19 Vaccine Resources that are Available to You

Arabic | Spanish | Korean | Russian | Simplified Chinese | Tagalog | Traditional Chinese | Vietnamese

Use the COVID-19 Resources to Share your Messages

  • Adapt the key messages to the language, tone, and format that will resonate with your community. You know what works in your community.
  • Customize this template letter and send or email it to your community members to introduce your COVID-19 vaccine educational activities.
  • Print copies of the posters and use them as handouts or to hang in highly visible places in your community.
  • Organize a COVID-19 vaccine presentation for your community members and promote it via digital and community communication channels. If your community has internet access, organize a virtual presentation. If it does not, organize an in-person presentation following COVID-19 safety precautions. Ask if your local health department can provide a speaker if you do not have a health educator on staff.
  • Continue to educate your community via articles, blog posts, and CDC social media posts or retweet and share CMS Medicare social media messages on Twitter and Facebook.
  • Invite community members to wear stickers once they have been vaccinated and post vaccination selfies on social media.

Communicate with Your Community

  • Send an introductory letter to encourage your branches, chapters, or affiliates to review and use the toolkit materials, or a letter to members of your organization.
  • Drop the newsletter content into your e-newsletters or listservs to distributed and share information widely on COVID-19 vaccines.
  • Use the COVID-19 Vaccine Basic slide deck for virtual town halls or other informational meetings within your communities. You can use all or part of the set or also include your own organization’s information. Slides are also available in Spanish.
  • Share these key messages about COVID-19 vaccine to educate your communities. These key messages are also available in a printable PDF version.
  • Use the Frequently Asked Questions (FAQs) to help answer questions about COVID-19 vaccine in your communities. FAQs also available in a printable PDF version.
  • Share credible and accurate COVID-19 vaccine information from the Myths & Facts page.
  • Encourage your community members who are vaccinated to enroll in v-safe an after vaccination health checker.

Questions? Please e-mail us: Partnership@cms.hhs.gov

FDA Issues Emergency Use Authorization for Third COVID-19 Vaccine

Action Advances Fight Against COVID-19, Follows Comprehensive Evaluation of Available Safety, Effectiveness and Manufacturing Quality Information by FDA Career Scientists, Input from External Experts

The U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the third vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARSCoV-2). The EUA allows the Janssen COVID-19 Vaccine to be distributed in the U.S for use in individuals 18 years of age and older.
“The authorization of this vaccine expands the availability of vaccines, the best medical prevention method for COVID-19, to help us in the fight against this pandemic, which has claimed over half a million lives in the United States,” said Acting FDA Commissioner Janet Woodcock, M.D. “The FDA, through our open and transparent scientific review process, has now authorized three COVID-19 vaccines with the urgency called for during this pandemic, using the agency’s rigorous standards for safety, effectiveness and manufacturing quality needed to support emergency use authorization.”
The FDA has determined that the Janssen COVID-19 Vaccine has met the statutory criteria for issuance of an EUA. The totality of the available data provides clear evidence that the Janssen COVID-19 Vaccine may be effective in preventing COVID-19. The data also show that the vaccine’s known and potential benefits outweigh its known and potential risks, supporting the company’s request for the vaccine’s use in people 18 years of age and older. In making this determination, the FDA can assure the public and medical community that it has conducted a thorough evaluation of the available safety, effectiveness and manufacturing quality information.
Click HERE to download and print the entire FDA News Release.